Each coated tablet contains: Losartan 50 mg. Excipients: q.s.

Therapeutic Action
Peripheral vasodilator antagonist of angiotensin 2 receptors type AT1.

Treatment of arterial hypertension in all its degrees of severity. Losartan may be used alone or in combination with other antihypertensive drugs.
Reduction on the risk of cardiovascular morbidity and mortality in patients with left ventricular hypertrophy:
Losartan is indicated to reduce the risk of cardiovascular mortality and composite cardiovascular morbidity (cardiovascular death, stroke and nonfatal infarction).
Nephropathy in patients with type II diabetes:
Losartan is indicated for the treatment of diabetic nephropathy with elevated serum creatinine and proteinuria (urinary creatinine albumin ratio ≥ 300 mg / g) in patients with type II diabetes and a history of hypertension. In this population, Losartan reduces the risk of progression of nephropathy measured through doubling of serum creatinine or terminal renal disease (need for dialysis or renal transplantation).
Heart failure:
Losartan is indicated for the treatment of heart failure when treatment with angiotensin converting enzyme (ACE) inhibitors is no longer adequate.
It is not recommended to switch to Losartan in patients with heart failure who have been stabilized with ACE inhibitors. Patients should have a ≤ 40% left ventricular ejection fraction and must be clinically stable and in a regimen of established treatment for chronic heart failure.

Blister box containing 30 coated tablets.